Santhera Doubles Its DMD Portfolio By Taking Option On Vamorolone

 
• By Joseph Haas

Deal Snapshot: Santhera acquires all rights to vamorolone from Idorsia, making it ReveraGen’s direct partner on the novel Duchenne muscular dystrophy therapy.

Handshake of businessmen
Santhera gets global rights to vamorolone by exercising option

More from Deals

More from Business